Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.GRAY · Entity 7804 | Director | March 23, 2023 | March 27, 2023 |
| DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930 | Director | May 23, 2024 | May 28, 2024 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | May 14, 2026 | May 18, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · CEO & President | February 06, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date March 23, 2023 · Filed March 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,429 |
Reported balance
After 2023-03-23 transaction · row 1
1 source rowRow 1 · 2023-03-23 · Disposition to issuer · Acquired 1,429 · Balance 1,429 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-23 · Disposition to issuer · Disposed 1,429 · Balance 0 F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
DYNAVAX TECHNOLOGIES CORP
Report date May 23, 2024 · Filed May 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,071 |
Reported balance
After 2024-05-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 5,357 · Balance 16,071 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2031-05-22 | Direct | 22,500 |
Reported balance
After 2024-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-23 · Grant · Acquired 22,500 · Balance 22,500 F2: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.
F2: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.
Lantheus Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,019 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 8,019 |
Zentalis Pharmaceuticals, Inc.
Report date February 06, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,133 |
Ending reported balance
After 2026-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-06 · Sale · Disposed 7,866 · Balance 80,022 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Row 2 · 2026-02-09 · Sale · Disposed 889 · Balance 79,133 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cascadian Therapeutics, Inc.
Report date March 09, 2018 · Filed March 13, 2018
Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 1
1 source rowRow 1 · 2018-03-09 · Other · Disposed 5,237 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.86 · Expires 2018-11-10 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-09 · Disposition to issuer · Disposed 6,667 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of November 10, 2010, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.92 · Expires 2018-12-01 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-09 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F4: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.52 · Expires 2019-12-01 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-09 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F5: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.44 · Expires 2020-12-12 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-09 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F6: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2021-12-12 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-09 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F7: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2022-12-16 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-03-09 · Disposition to issuer · Disposed 16,667 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F8: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2023-09-24 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-03-09 · Disposition to issuer · Disposed 41,667 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F9: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2024-05-17 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-03-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F11: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $155,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F10: 25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2027-01-11 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-03-09 · Disposition to issuer · Disposed 51,200 · Balance 0 F13: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F12: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2027-09-18 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-03-09 · Disposition to issuer · Disposed 75,000 · Balance 0 F15: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $450,750.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F14: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-03-09 · Disposition to issuer · Disposed 11,300 · Balance 0 F16: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F17: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-03-09 · Disposition to issuer · Disposed 16,500 · Balance 0 F19: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F20: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-03-09 · Disposition to issuer · Disposed 199,000 · Balance 0 F21: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F22: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years. F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of November 10, 2010, and the remainder vest monthly thereafter for 36 months.
F3: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price.
F4: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months.
F5: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months.
F6: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months.
F7: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months.
F8: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months.
F9: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months.
F10: 25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months.
F11: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $155,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
F12: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months.
F13: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
F14: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months.
F15: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $450,750.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
F16: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F17: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
F18: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
F19: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F20: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
F21: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F22: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 269,381 |
Reported balance
After 2024-03-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-11 · Grant · Acquired 31,250 · Balance 269,381 F1: Reflects the number of restricted stock units ("RSUs") vested upon the achievement of certain performance-related metrics. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), issuable upon the vesting of RSUs. F2: Includes 6,128 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 29, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-03-11 · Disposition to issuer · Disposed 269,381 · Balance 0 F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F4: Includes 259,750 RSUs. F5: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Disposition to issuer · Disposed 2,765 · Balance 0 F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.90 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-11 · Disposition to issuer · Disposed 40,759 · Balance 0 F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F8: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of restricted stock units ("RSUs") vested upon the achievement of certain performance-related metrics. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), issuable upon the vesting of RSUs.
F2: Includes 6,128 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 29, 2024.
F3: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F4: Includes 259,750 RSUs.
F5: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
F7: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the
F8: (Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2018 Filed Mar 13, 2018 18:01 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerStock Option (Right to buy) · Derivative | 8,334 | Not disclosed Strike: $19.92 | Not disclosed |
DisclosureSEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 3 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,334 shares Expires 2018-12-01 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:01 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerStock Option (Right to buy) · Derivative | 6,667 | Not disclosed Strike: $19.86 | Not disclosed |
DisclosureSEC source: 0000899243-18-007292 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2018-11-10 F3 · price: Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of November 10, 2010, and the remainder vest monthly thereafter for 36 months. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:01 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | OtherCommon Stock | 5,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007292 · doc4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 17:54 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 199,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007134 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,000 Underlying: Common Stock · 199,000 shares Expires 2022-02-01 F1 · derivative.exercise_price: Approximately 70% of each RSU represents a contingent right to receive approximately 0.70 share of the issuer's Common Stock upon vesting and approximately 30% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of February 1, 2019, February 1, 2020, February 1, 2021 and February 1, 2022, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:25 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionRestricted Share Unit (RSU) · Derivative | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003645 · doc4.xml · derivative · entry 3 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,475 Underlying: Common Stock · 2,825 shares Expires 2027-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:25 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Tax withholdingCommon Stock | 923 | $3.92 | $3,618.16 |
DisclosureSEC source: 0001209191-18-003645 · doc4.xml · nonDerivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237 F1 · shares: 923 shares of the restricted share unit ("RSU") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 923 shares of the restricted share unit ("RSU") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:25 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionCommon Stock | 2,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003645 · doc4.xml · nonDerivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 21:10 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053537 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2021-09-18 F2 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 21:10 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-17-053537 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-09-18 F1 · derivative.exercise_date: The option vests and is exercisable at the rate of 1/4th of the total shares on September 18, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 19:47 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 11,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-003756 · doc4.xml · derivative · entry 2 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & VP Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2021-01-11 F2 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 19:47 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantStock Option (right to buy) · Derivative | 51,200 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001209191-17-003756 · doc4.xml · derivative · entry 1 EASTLAND JULIA MARIE · CIK 0001500189 · CFO & VP Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,200 Underlying: Common Stock · 51,200 shares Expires 2027-01-11 F1 · derivative.exercise_date: The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.